Technical Analysis for CCEL - Cryo-Cell International, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 1.76% | |
| Wide Range Bar | Range Expansion | 1.76% | |
| Stochastic Reached Oversold | Weakness | 11.11% | |
| Strong but Oversold | Other | 11.11% |
| Alert | Time |
|---|---|
| Reversed from Down | about 12 hours ago |
| 20 DMA Support | about 12 hours ago |
| 10 DMA Support | about 12 hours ago |
| Gap Up Closed | about 13 hours ago |
| Down 5% | about 13 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 04/19/2024
Cryo-Cell International, Inc. Description
Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in Los Angeles and Baptist Hospital in Miami. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-compliant and licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. Cryo-Cell owns the exclusive rights to PrepaCyte-CB, the industry’s most advanced cord blood processing technology.
Classification
Sector: Healthcare
Industry: Medical Care Facilities
Keywords: Biology Stem Cell FDA Blood Childbirth Cord Blood
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.15 |
| 52 Week Low | 3.67 |
| Average Volume | 12,138 |
| 200-Day Moving Average | 5.68 |
| 50-Day Moving Average | 6.22 |
| 20-Day Moving Average | 7.32 |
| 10-Day Moving Average | 7.22 |
| Average True Range | 0.53 |
| RSI (14) | 60.94 |
| ADX | 22.29 |
| +DI | 28.98 |
| -DI | 17.21 |
| Chandelier Exit (Long, 3 ATRs) | 6.57 |
| Chandelier Exit (Short, 3 ATRs) | 7.08 |
| Upper Bollinger Bands | 8.09 |
| Lower Bollinger Band | 6.54 |
| Percent B (%b) | 0.62 |
| BandWidth | 21.17 |
| MACD Line | 0.26 |
| MACD Signal Line | 0.34 |
| MACD Histogram | -0.0776 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.35 | ||||
| Resistance 3 (R3) | 9.32 | 8.69 | 9.04 | ||
| Resistance 2 (R2) | 8.69 | 8.22 | 8.70 | 8.94 | |
| Resistance 1 (R1) | 8.09 | 7.93 | 7.78 | 8.12 | 8.83 |
| Pivot Point | 7.46 | 7.46 | 7.30 | 7.47 | 7.46 |
| Support 1 (S1) | 6.86 | 6.99 | 6.54 | 6.88 | 6.17 |
| Support 2 (S2) | 6.23 | 6.70 | 6.24 | 6.06 | |
| Support 3 (S3) | 5.63 | 6.23 | 5.96 | ||
| Support 4 (S4) | 5.65 |
